Replies to post #742107 on NorthWest Biotherapeutics Inc (NWBO)

[XMaster2023]

The Shorts would like us to forget 5/10/22 as there is a mountain of evidence that points to the manipulation efforts by the market makers.
I watched the price start falling prior to any announcement or news. The market makers need to pay for their greed on that day.

[jtaylor042]

If you believe that 5/10/22 was mishandled by NWBO then you are either woefully naïve or hugely complicit in the coordinated short attack on the company, by the co-conspirators, complete with lies and a pre-written hit piece by the hired gun, Fraudstein. It was totally fabricated and criminal!

Hold up there chief, are you saying there are no legit criticisms of the company for events of 5.10?

(We didn't even halt for news - how is that not at least one legit critique of that day?)

[HappyLibrarian]

Misstep 1:

NWBo failed to ensure that the DCVax-L Phase 3 trial information update clinicaltrials.gov with the correct primary endpoint in a timely fashion after the endpoint change in Europe became public knowledge?

The discrepancy between what was said about the trial in different jurisdictions created confusion for years and allowed the idea that Europe had accepted the change but not the US to have a sliver of credibility. NWBO shareholders noted this problem often and unless the company was blind deaf and dumb, they were aware and chose to ignore the need update clinicialtrials.gov. Truth to tell they were probably upset we learned about the endpoint change in Europe.

As I recall Adam Feuerstein was able to exploit this misstep of not updating official information and claim that DCVax-L had failed on its primary endpoint when that claim would not have had a fig leaf to cover it if both Europe and the US were in accord.

Misstep 2:

NWBO allowed a 3rd party whose primary purpose was not amplifying the news for the benefit of shareholders to release TLD and those they entrusted managed to foreground the bad news about PFS instead of the good news about OS.

NWBO meanwhile practically sat on their hands on media and investor relations.

Misstep 3:

NWBO delayed TLD release from the original September 2020 to May 10, 2022 by holding back TLD ostensibly so that a major journal article could bolster its credibility and cover any weaknesses. This was the plan their supporters on here trumpeted day after day from October 5, 2020 until May 10, 2022

NWBO failed go follow through on the expectation the market reasonably had that a JA was coming on May 10, 2022 because obviously NWBO was not releasing TLD with no JA. This right there would hurt market sentiment.

So NWBO and patients got the worst of both worlds, by backing up TLD for the sake of a JA they failed to use, they backed up MHRA approval for almost 3 more years after TLD release and a total of 4 1/2 years from when data lock happened.

Those are years of lost lives and lost revenue which could have helped the share price etc. and could have made it a lot easier to pay for the automation development efforts using the Flaskworks tech.